Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$4.73M | -$11.2M | -$34.4M |
| Net income | -$5.31M | -$11.2M | -$47.3M |
| EPS (diluted) | -$1.53 | -$1.16 | -$2.74 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$4.16M | -$10.2M | -$22.8M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $1.72M | $4.16M | $8.71M |
| Total assets | $1.89M | $5.65M | $10.1M |
| Total liabilities | $782K | $2.51M | $10.0M |
| Shareholders' equity | $1.11M | $3.13M | -$67.6K |
| Retained earnings | -$17.7M | -$28.9M | -$64.3M |
| Shares (wtd avg diluted) | 3.48M | 9.62M | 17.3M |
Every figure is extracted from Medicus Pharma Ltd.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.